Bio-Rad Laboratories acquired Stilla Technologies and Norman Schwartz was appointed as Chairman and CEO.
2 reports, 2 independent
Updated Aug 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bio-Rad Laboratories acquired Stilla Technologies and Norman Schwartz was appointed as Chairman and CEO.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
Related events
Coverage
Newest first; wire copies grouped- Business WireBio-Rad Reports Second-Quarter 2025 Financial Results HERCULES, Calif., July 31, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and
- ZacksBio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instru